Agile Therapeutics Inc banner
A

Agile Therapeutics Inc
OTC:AGRX

Watchlist Manager
Agile Therapeutics Inc
OTC:AGRX
Watchlist
Price: 0.6022 USD
Market Cap: $10.4m

AGRX's latest stock split occurred on Apr 11, 2023

The company executed a 1-for-50 stock split, meaning that for every 50 shares held, investors received 1 new share.

Before the split, AGRX traded at 0.2066 per share. Afterward, the share price was about 8.17.

The adjusted shares began trading on Apr 11, 2023. This was AGRX's 2nd stock split, following the previous one in Apr 27, 2022.

Last Splits:
Apr 11, 2023
1-for-50
Apr 27, 2022
1-for-40
Pre-Split Price
10.33 0.2066
Post-Split Price
8.17
Before
After
Last Splits:
Apr 11, 2023
1-for-50
Apr 27, 2022
1-for-40

Agile Therapeutics Inc
Stock Splits History

AGRX Stock Splits Timeline
Apr 11, 2023
Apr 11, 2023
Split 1-for-50
/0.02
Pre-Split Price
10.33 0.2066
Post-Split Price
8.17
Before
After
Apr 27, 2022
Apr 27, 2022
Split 1-for-40
/0.025
Pre-Split Price
223.8 0.1119
Post-Split Price
157
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 23, 2026
Red Sky Energy Ltd
ASX:ROG
5-for-4
x1.25
0.002 0.0016 AUD 0.002 0.002 AUD
Apr 23, 2026
S
Saudee Group Bhd
KLSE:SAUDEE
1-for-10
/10
0.01 0.1 MYR 0.09 0.09 MYR
Apr 23, 2026
Focus Technology Co Ltd
SZSE:002315
1-for-1
x1
44.3999 33.4538 CNY 32 32 CNY
Load More

Agile Therapeutics Inc
Glance View

Market Cap
10.4m USD
Industry
Pharmaceuticals

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. The company is headquartered in Princeton, New Jersey and currently employs 30 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

AGRX Intrinsic Value
Not Available
A
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett